Terms: = Ovarian cancer AND MYD88, Q99836, MYD88D, 4615 AND Treatment
23 results:
1. P53 and TLR4 expression are prognostic markers informing progression free survival of advanced stage high grade serous ovarian cancer.
Bates M; Mullen D; Lee E; Costigan D; Heron EA; Kernan N; Barry-O'Crowley J; Martin C; Keegan H; Malone V; Brooks RD; Brooks DA; Logan JM; Martini C; Selemidis S; McFadden J; O'Riain C; Spillane CD; Gallagher MF; McCann A; O'Toole S; O'Leary JJ
Pathol Res Pract; 2024 Jan; 253():155020. PubMed ID: 38103365
[TBL] [Abstract] [Full Text] [Related]
2. The role of the MAD2-TLR4-myd88 axis in paclitaxel resistance in ovarian cancer.
Bates M; Spillane CD; Gallagher MF; McCann A; Martin C; Blackshields G; Keegan H; Gubbins L; Brooks R; Brooks D; Selemidis S; O'Toole S; O'Leary JJ
PLoS One; 2020; 15(12):e0243715. PubMed ID: 33370338
[TBL] [Abstract] [Full Text] [Related]
3. Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in ovarian cancer.
Baert T; Vankerckhoven A; Riva M; Van Hoylandt A; Thirion G; Holger G; Mathivet T; Vergote I; Coosemans A
Front Immunol; 2019; 10():1273. PubMed ID: 31214202
[TBL] [Abstract] [Full Text] [Related]
4. TLR4 blockade using TAK-242 suppresses ovarian and breast cancer cells invasion through the inhibition of extracellular matrix degradation and epithelial-mesenchymal transition.
Zandi Z; Kashani B; Poursani EM; Bashash D; Kabuli M; Momeny M; Mousavi-Pak SH; Sheikhsaran F; Alimoghaddam K; Mousavi SA; Ghaffari SH
Eur J Pharmacol; 2019 Jun; 853():256-263. PubMed ID: 30930249
[TBL] [Abstract] [Full Text] [Related]
5. P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling.
de Almeida Chuffa LG; de Moura Ferreira G; Lupi LA; da Silva Nunes I; Fávaro WJ
J Ovarian Res; 2018 Jan; 11(1):8. PubMed ID: 29343281
[TBL] [Abstract] [Full Text] [Related]
6. Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance.
Edwardson DW; Boudreau J; Mapletoft J; Lanner C; Kovala AT; Parissenti AM
PLoS One; 2017; 12(9):e0183662. PubMed ID: 28915246
[TBL] [Abstract] [Full Text] [Related]
7. Galectin-3 induces ovarian cancer cell survival and chemoresistance via TLR4 signaling activation.
Cai G; Ma X; Chen B; Huang Y; Liu S; Yang H; Zou W
Tumour Biol; 2016 Sep; 37(9):11883-11891. PubMed ID: 27059733
[TBL] [Abstract] [Full Text] [Related]
8. TRX-E-002-1 Induces c-Jun-Dependent Apoptosis in ovarian cancer Stem Cells and Prevents Recurrence In Vivo.
Alvero AB; Heaton A; Lima E; Pitruzzello M; Sumi N; Yang-Hartwich Y; Cardenas C; Steinmacher S; Silasi DA; Brown D; Mor G
Mol Cancer Ther; 2016 Jun; 15(6):1279-90. PubMed ID: 27196760
[TBL] [Abstract] [Full Text] [Related]
9. MiRNA-149 modulates chemosensitivity of ovarian cancer A2780 cells to paclitaxel by targeting myd88.
Zhan Y; Xiang F; Wu R; Xu J; Ni Z; Jiang J; Kang X
J Ovarian Res; 2015 Jul; 8():48. PubMed ID: 26223974
[TBL] [Abstract] [Full Text] [Related]
10. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in myd88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract] [Full Text] [Related]
11. A novel serum microRNA panel to discriminate benign from malignant ovarian disease.
Langhe R; Norris L; Saadeh FA; Blackshields G; Varley R; Harrison A; Gleeson N; Spillane C; Martin C; O'Donnell DM; D'Arcy T; O'Leary J; O'Toole S
Cancer Lett; 2015 Jan; 356(2 Pt B):628-36. PubMed ID: 25451316
[TBL] [Abstract] [Full Text] [Related]
12. Myeloid differentiation factor 88 promotes cisplatin chemoresistance in ovarian cancer.
Liu G; Du P; Zhang Z
Cell Biochem Biophys; 2015 Mar; 71(2):963-9. PubMed ID: 25308861
[TBL] [Abstract] [Full Text] [Related]
13. Multiple blocks in the engagement of oxidative phosphorylation in putative ovarian cancer stem cells: implication for maintenance therapy with glycolysis inhibitors.
Alvero AB; Montagna MK; Sumi NJ; Joo WD; Graham E; Mor G
Oncotarget; 2014 Sep; 5(18):8703-15. PubMed ID: 25237928
[TBL] [Abstract] [Full Text] [Related]
14. Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/myd88-dependent pathway.
Huang JM; Zhang GN; Shi Y; Zha X; Zhu Y; Wang MM; Lin Q; Wang W; Lu HY; Ma SQ; Cheng J; Deng BF
Sci Rep; 2014 Jan; 4():3840. PubMed ID: 24452475
[TBL] [Abstract] [Full Text] [Related]
15. Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment.
Craveiro V; Yang-Hartwich Y; Holmberg JC; Joo WD; Sumi NJ; Pizzonia J; Griffin B; Gill SK; Silasi DA; Azodi M; Rutherford T; Alvero AB; Mor G
Cancer Med; 2013 Dec; 2(6):751-62. PubMed ID: 24403249
[TBL] [Abstract] [Full Text] [Related]
16. Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy.
Mascia F; Lam G; Keith C; Garber C; Steinberg SM; Kohn E; Yuspa SH
Sci Transl Med; 2013 Aug; 5(199):199ra110. PubMed ID: 23966299
[TBL] [Abstract] [Full Text] [Related]
17. Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment.
Baird JR; Fox BA; Sanders KL; Lizotte PH; Cubillos-Ruiz JR; Scarlett UK; Rutkowski MR; Conejo-Garcia JR; Fiering S; Bzik DJ
Cancer Res; 2013 Jul; 73(13):3842-51. PubMed ID: 23704211
[TBL] [Abstract] [Full Text] [Related]
18. TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence.
Chefetz I; Alvero AB; Holmberg JC; Lebowitz N; Craveiro V; Yang-Hartwich Y; Yin G; Squillace L; Gurrea Soteras M; Aldo P; Mor G
Cell Cycle; 2013 Feb; 12(3):511-21. PubMed ID: 23324344
[TBL] [Abstract] [Full Text] [Related]
19. Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells.
Alvero AB; Montagna MK; Holmberg JC; Craveiro V; Brown D; Mor G
Mol Cancer Ther; 2011 Aug; 10(8):1385-93. PubMed ID: 21677151
[TBL] [Abstract] [Full Text] [Related]
20. The role of cancer stem cells and the side population in epithelial ovarian cancer.
Fong MY; Kakar SS
Histol Histopathol; 2010 Jan; 25(1):113-20. PubMed ID: 19924647
[TBL] [Abstract] [Full Text] [Related]
[Next]
